🇺🇸 FDA
Pipeline program

Cemiplimab-Rwlc

20200543

Phase 2 small_molecule terminated

Quick answer

Cemiplimab-Rwlc for Head and Neck Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Head and Neck Squamous Cell Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials